Literature DB >> 2581727

Preparation and characterization of monoclonal antibodies specific to placenta ferritin.

C Moroz, B Kupfer, S Twig, B Parhami-Seren.   

Abstract

Ferritins are a group of isomeric proteins which function as the major iron-storage protein of mammalian tissues. Some of the isoferritins have low isoelectric points, and are found in placenta and in malignant tissues and have therefore been termed carcinofetal ferritins. With the use of hybridoma technology, monoclonal antibodies (McAbs) specific to human placenta ferritin(s) were produced in order to characterize the heterogeneity of the molecule and to answer the question whether a specific antigenic determinant is associated with placenta and/or carcinofetal ferritin(s). Two McAbs designated H-9 and G-8 were developed. McAb H-9 bound specifically and exclusively to the ferritin isolated from human placenta, whereas G-8 McAb bound to placenta ferritin and cross-reacted with ferritins isolated from human spleen and liver. No cross-reaction was observed between H-9 and G-8 reactive determinants. It was found further that the two antigenic determinants - the one recognized by G-8 and that recognized by H-9 McAbs - are molecularly associated on placenta ferritin. The results of this study led us to term the G-8 a 'common' ferritin antigenic determinant and H-9 a 'private' embryonic ferritin determinant.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2581727     DOI: 10.1016/0009-8981(85)90220-7

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  12 in total

1.  Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer.

Authors:  H R Rosen; C Moroz; A Reiner; M Reinerova; M Stierer; J Svec; M Schemper; R Jakesz
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Serum placental isoferritin and breast cancer prognosis.

Authors:  M Stierer; H R Rosen; C Moroz
Journal:  Breast Cancer Res Treat       Date:  1990-11       Impact factor: 4.872

3.  T-cell mitogenesis stimulates the synthesis of a mRNA species coding for a 43-kDa peptide reactive with CM-H-9, a monoclonal antibody specific for placental isoferritin.

Authors:  C Moroz; N Shterman; B Kupfer; I Ginzburg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Placental isoferritin as a physiological downregulator of cellular immunoreactivity during pregnancy.

Authors:  L Sirota; B Kupfer; C Moroz
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

5.  FBL blood test as a predictive marker of breast cancer in high risk women.

Authors:  C Moroz; A Chetrit; M Kahn; B Modan
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

6.  Elevated serum placental isoferritin in newly diagnosed type 1 (insulin-dependent) diabetes mellitus. A possible marker for identification of high risk subjects.

Authors:  S Assa; C Moroz
Journal:  Diabetologia       Date:  1990-09       Impact factor: 10.122

7.  The immunosuppressive human placental ferritin subunit p43 is produced by activated CD4+ lymphocytes.

Authors:  B Garty; E Kaminsky; C Moroz
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

8.  Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study.

Authors:  M Stierer; H R Rosen; E Forster; C Moroz
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

9.  Difference in the placental ferritin levels measured by a specific monoclonal antibody enzymoassay in preterm and term delivery.

Authors:  C Moroz; H Bessler; L Sirota; F Dulitzky; M Djaldetti
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

10.  Antibodies to placental immunoregulatory ferritin with transfer of polyclonal lymphocytes arrest MCF-7 human breast cancer growth in a nude mouse model.

Authors:  Marisa Halpern; Muayad A Zahalka; Leonid Traub; Chaya Moroz
Journal:  Neoplasia       Date:  2007-06       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.